Skip to main content

The Asthma and Allergy Foundation of America is sharing this press release from kaléo to bring you the latest news quickly.


[PRESS RELEASE]

Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide

  • Walgreens becomes first retail pharmacy to offer access to AUVI-Q auto-injectors at no cost for commercially insured patients who are eligible for kaléo’s patient support programs.
  • For patients who are unable to fill their current epinephrine prescriptions, Walgreens pharmacists will work with each patient’s healthcare practitioner to see if AUVI-Q is right for them.

September 06, 2018 08:00 AM Eastern Daylight Time -- DEERFIELD, Ill. & RICHMOND, Va.--(BUSINESS WIRE)--Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

AUVI-Q is a prescription medicine approved by the FDA to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. AUVI-Q does not take the place of emergency medical care. Patients need to seek immediate medical treatment after using AUVI-Q.

Through the AUVI-Q AffordAbility program provided by kaléo, eligible patients with commercial insurance, even those with high-deductible plans, can obtain AUVI-Q at no cost. For eligible patients who do not have insurance or prescription drug coverage, kaléo may be able to support through its patient assistance program. Please see additional information on patient eligibility and the terms and conditions at www.auvi-q.com/getting-auvi-q/

Anaphylaxis is a serious allergic reaction that happens quickly and may cause death.1 Anaphylaxis can occur as a result of exposure to allergens including tree nuts, peanuts, milk, eggs, fish, shellfish, soy, wheat, insect bites, latex and medication, among other allergens. Reports estimate that up to 15 million Americans are living with food allergies.2

“The health and wellbeing of our customers is of the upmost importance,” said Richard Ashworth, Walgreens president of operations. “Walgreens pharmacists continue to care for and work with patients and their prescribers to ensure they have access to the epinephrine auto-injectors they need, and we’re pleased to work with kaléo to help meet the demand for epinephrine auto-injectors across the country.”

AUVI-Q’s innovative features include voice instructions that help guide a user step-by-step through the epinephrine delivery process, as well as an auto-retractable needle system, a first for epinephrine auto-injectors, that injects the epinephrine and retracts the needle back into the device within seconds.

“Thanks to this collaboration with Walgreens, any patient who is having difficulty filling a prescription for an epinephrine auto-injector now has the opportunity to get AUVI-Q through Walgreens,” said Phil Rackliffe, general manager of Allergy and Pediatrics at kaléo. “We are working with insurance providers to maximize coverage of AUVI-Q for as many patients as possible.”

For patients who are unable to fill their current epinephrine prescriptions, Walgreens pharmacists will work with each patient’s healthcare practitioner to see if AUVI-Q is right for them. Current AUVI-Q patients should continue to utilize kaléo’s Direct Delivery service at https://www.auvi-q.com/getting-auvi-q/ to ensure delivery to their home. AUVI-Q 0.15 mg and 0.3 mg are available through Walgreens for patients with commercial insurance. Medicare patients should check with their individual health plan to verify their specific benefits, as AUVI-Q coverage varies by Medicare plan.

To learn more about AUVI-Q, please visit www.auvi-q.com.

About Walgreens

Walgreens (walgreens.com), one of the nation's largest drugstore chains, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. Approximately 8 million customers interact with Walgreens in stores and online each day, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. As of June 28, 2018, Walgreens operates approximately 9,800 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands, along with its omnichannel business, Walgreens.com. Approximately 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.

About kaléo (kuh-LAY-oh)

Kaléo is a new type of pharmaceutical company, dedicated to building innovative solutions for serious and life-threatening medical conditions. We believe patients and caregivers are the experts on how their medical condition impacts their lives and are an integral part of our product development process. Kaléo is a privately-held company headquartered in Richmond, Virginia. For more information, visit www.kaleo.com.

About AUVI-Q (0.3 mg, 0.15 mg and 0.1 mg)

AUVI-Q (epinephrine injection, USP) Auto-injector is a prescription medicine used to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or who have a history of serious allergic reactions. AUVI-Q contains epinephrine, a first-line treatment for allergic reactions that occur as a result of exposure to allergens including food such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings or bites; latex and medication, among other allergens and causes.

AUVI-Q is the only compact epinephrine auto-injector with a voice instruction system that helps guide patients and caregivers step-by-step through the injection process, and a needle that automatically retracts following administration. In anaphylaxis emergencies, it is often individuals without medical training who need to step in and deliver potentially life-saving epinephrine. AUVI- Q was designed through careful analysis of the situations where epinephrine auto-injectors are used and with significant input from the allergy community that relies on it incorporating Human Factors Engineering (HFE). HFE is about designing products or systems that are easy to operate and, most importantly, support correct use, with the goal to remove the potential for error. For more information about AUVI-Q (0.3 mg, 0.15 mg and 0.1 mg) visit www.auvi-q.com.

Contacts
Allison Mack
Walgreens
847-226-9750
allison.mack@walgreens.com

or

Mark A. Herzog
Kaléo
804-545-6360
Mark.Herzog@kaleo.com

References

1. Lieberman, P. (2015). Anaphylaxis After Cystoscopy. The Journal of Allergy and Clinical Immunology: In Practice, 3(3), 469-470. doi:10.1016/j.jaip.2014.05.007

2. Facts and Statistics. Facts and Statistics – Food Allergy Research & Education. https://www.foodallergy.org/facts-and-stats. Accessed September 4, 2018.

Join our community to follow our blog for the latest news on asthma and allergy research and treatments. Our community also provides an opportunity to connect with others who manage these conditions for peer support.

JOIN NOW

Add Comment

×
×
×
Link copied to your clipboard.
×